Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO).
Iwein GyselinckLaurens LiesenborghsAnn BelmansMatthias M EngelenAlbrecht BetrainsQuentin Van ThilloPham Anh Hong NguyenPieter GoeminneAnn-Catherine SoenenNikolaas De MaeyerCharles PiletteEmmanuelle PapleuxEef VanderhelstAurélie DerweduwenPatrick AlexanderBernard BouckaertJean-Benoît MartinotLynn DecosterKurt VandeurzenRob SchildermansPeter VerhammeWim JanssensRobin VosPublished in: ERJ open research (2022)
Time to clinical improvement is not influenced by azithromycin in patients hospitalised with moderate to severe COVID-19.
Keyphrases
- clinical trial
- open label
- study protocol
- sars cov
- end stage renal disease
- double blind
- phase ii
- chronic kidney disease
- ejection fraction
- coronavirus disease
- newly diagnosed
- phase iii
- phase ii study
- peritoneal dialysis
- randomized controlled trial
- prognostic factors
- early onset
- squamous cell carcinoma
- radiation therapy
- community acquired pneumonia
- placebo controlled